A pilot study of Topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes.

In this study for the first time in alcohol withdrawal syndrome, the response to topiramate was assessed. 12 patients with median age of 49.5 years and median body weight of 76.3 kg were treated with topiramate twice daily for up 30 days, starting with a dose of 50 mg in the morning and 50 mg in the evening. The preliminary findings of this study suggest that topiramate is very effective against tonic-clonic seizures in alcohol withdrawal syndrome. No side effects were observed. Only two patients had loss of body weight (3-3.5 kg/4 weeks).
AuthorsAvdo Rustembegovic, Emin Sofic, Gerhard Kroyer
JournalMedicinski arhiv (Med Arh) Vol. 56 Issue 4 Pg. 211-2 ( 2002) Bosnia and Herzegovina
PMID12518536 (Publication Type: Journal Article)
Chemical References
  • Anticonvulsants
  • topiramate
  • Fructose
  • Alcohol Withdrawal Seizures (drug therapy)
  • Anticonvulsants (therapeutic use)
  • Epilepsy, Tonic-Clonic (drug therapy, etiology)
  • Fructose (analogs & derivatives, therapeutic use)
  • Humans
  • Middle Aged
  • Pilot Projects

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: